We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Intersect ENT Inc | NASDAQ:XENT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.25 | 28.16 | 28.36 | 0 | 00:00:00 |
From Dec 2019 to Dec 2024
By Colin Kellaher
Shares of Intersect ENT Inc. rose more than 12% on Friday after the drug-delivery company agreed to be acquired by medical-technology giant Medtronic PLC.
Dublin-based Medtronic agreed to pay $28.25 a share in cash for Intersect, a 15% premium to Thursday's closing price of $24.52, in a deal with an implied enterprise value of around $1.1 billion.
Intersect, based in Menlo Park, Calif., makes devices used by ear, nose and throat doctors to treat sinusitis. Medtronic said the addition of Intersect's Propel and Sinuva sinus implants, which open sinus passageways and deliver an anti-inflammatory steroid to aid in healing, will bolster its offerings for patients with chronic rhinosinusitis.
Intersect shares were recently up about 12.2% to $27.50.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 06, 2021 10:16 ET (14:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Intersect ENT Chart |
1 Month Intersect ENT Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
